Plans & Pricing
Where will iPS cells be a year from today?
Pretty much where they are today (no major steps either way)
It will be clear that iPS cells have little clinical potential due to safety issues (two steps back)
Some proof of safety and efficacy in pre-clinical studies (two steps forward)
The focus will shift mostly to disease modeling in a dish, not use in cellular therapy (step to the side)
Trans-differentiation will take the lead from iPS cells (one step forward for trans-differentiation; one step back for iPS)
Posted 8 years.
See this poll on:
Leave a Comment
Please enter your name.
Please enter your email address.
Your Website (optional)
Please enter a comment.